Active	Status	Sponsor type	Region	Phase	Filter
8 Active 2 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rastogi, Anjay
EAGLE, NCT03749447 / 2018-003253-24: An Extended Access Program for Bardoxolone Methyl in Patients With CKD	Terminated	3	270	Europe, Japan, US, RoW	Bardoxolone methyl, RTA 402	Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc.	Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney	08/23	08/23
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -	Terminated	3	667	Europe, Japan, US, RoW	Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule	Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC	Autosomal Dominant Polycystic Kidney, ADPKD	08/23	08/23
ALIGN, NCT04573478: Atrasentan in Patients With IgA Nephropathy	Active, not recruiting	3	404	Europe, Canada, Japan, US, RoW	Atrasentan, CHK-01, Atrasentan Hydrochloride, ABT-627, Placebo	Chinook Therapeutics, Inc.	IgA Nephropathy, Immunoglobulin A Nephropathy	12/26	12/26
PERIDOT, NCT05206773 / 2021-002350-90: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease	Active, not recruiting	3	122	Europe, Canada, Japan, US, RoW	Venglustat (GZ402671), Placebo	Sanofi, Sanofi-Aventis Recherche & Développement	Fabry Disease	12/25	12/26
Wallace, Eric L
PERIDOT, NCT05206773 / 2021-002350-90: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease	Active, not recruiting	3	122	Europe, Canada, Japan, US, RoW	Venglustat (GZ402671), Placebo	Sanofi, Sanofi-Aventis Recherche & Développement	Fabry Disease	12/25	12/26
NCT04552691: Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients	Approved for marketing	N/A		US	Pegunigalsidase Alfa	Chiesi Farmaceutici S.p.A., Chiesi USA, Inc.	Fabry Disease
FROST-HF, NCT05136820: Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study	Active, not recruiting	N/A	698	US	Atrial Flow Regulator, AFR, Sham Comparator	Occlutech International AB	Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Reduced Ejection Fraction (HFrEF)	02/26	02/29
Mkrttchyan, Anita
PERIDOT, NCT05206773 / 2021-002350-90: A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease	Active, not recruiting	3	122	Europe, Canada, Japan, US, RoW	Venglustat (GZ402671), Placebo	Sanofi, Sanofi-Aventis Recherche & Développement	Fabry Disease	12/25	12/26